Citations

Clear

3138 citation(s) found for "Smith, AM".

Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization
Smith, Johanna L. , Tcheandjieu, Catherine , Dikilitas, Ozan , Iyer, Kruthika , Miyazawa, Kazuo , Hilliard, Austin T. , Lynch, Julie A. , Rotter, Jerome I. , Chen, Yii‐Der Ida , Sheu, Wayne Huey‐Herng , Kanoni, Stavroula , Tsao, Philip S. , Ito, Kaoru , Kosel, Matthew , Schaid, Daniel J. , Chen, Yii-Der Ida , Hilliard, Austin , Lynch, Julie A , Chang, Kyong-Mi , Kanoni, Stavroula , Tsao, Philip S , Ito, Kaoru , Kosel, Matthew , Clarke, Shoa L , Schaid, Daniel J , Assimes, Themistocles L , Kullo, Iftikhar J , Dikilitas, Ozan , Rotter, Jerome I , Chang, Kyong‐Mi , Clarke, Shoa L. , Assimes, Themistocles L. , Kullo, Iftikhar J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 21, 2024 | Volume: 17 | Issue: 3 | Pages: No page available

10.1161/circgen.123.004272 | PMID 38380516 Get It

BACKGROUND: Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate equitable clinical use, we developed PRS for coronary heart disease (CHD; PRS CHD ) for 5 genetic ancestry groups. METHODS: We derived ancestry-specific and multi-ancestry PRS CHD based on pruning and thresholding (PRS PT ) and ancestry-based continuous shrinkage priors (PRS CSx ) applied to summary statistics from the largest multi-ancestry genome-wide association study meta-analysis for CHD to date, including 1.1 million participants from 5 major genetic ancestry groups. Following training and optimization in the Million Veteran Program, we evaluated the best-performing PRS CHD in 176,988 individuals across 9 diverse cohorts. RESULTS: Multi-ancestry PRS PT and PRS CSx outperformed ancestry-specific PRS PT and PRS CSx across a range of tuning values. Two best-performing multi-ancestry PRS CHD (ie, PRS PTmult and PRS CSxmult ) and 1 ancestry-specific (PRS CSxEUR ) were taken forward for validation. PRS PTmult demonstrated the strongest association with CHD in individuals of South Asian ancestry and European ancestry (odds ratio per 1 SD [95% CI, 2.75 [2.41–3.14], 1.65 [1.59–1.72]), followed by East Asian ancestry (1.56 [1.50–1.61]), Hispanic/Latino ancestry (1.38 [1.24–1.54]), and African ancestry (1.16 [1.11–1.21]). PRS CSxmult showed the strongest associations in South Asian ancestry (2.67 [2.38–3.00]) and European ancestry (1.65 [1.59–1.71]), lower in East Asian ancestry (1.59 [1.54–1.64]), Hispanic/Latino ancestry (1.51 [1.35–1.69]), and the lowest in African ancestry (1.20 [1.15–1.26]). CONCLUSIONS: The use of summary statistics from a large multi-ancestry genome-wide meta-analysis improved the performance of PRS CHD in most ancestry groups compared with single-ancestry methods. Despite the use of one of the largest and most diverse sets of training and validation cohorts to date, improvement of predictive performance was limited in African ancestry. This highlights the need for larger genome-wide association study datasets of underrepresented populations to enhance the performance of PRS CHD .
Cardiac Magnetic Resonance Imaging in Heart Transplant Recipients with Biopsy-Negative Graft Dysfunction
Anand, Senthil, Alnsasra, Hilmi , LeMond, Lisa , Shrivastava, Sanskriti , Rosenbaum, Andrew , Kobrossi, Semaan, Mohananey, Akanksha, Murphy, Katie , Kushwaha, Sudhir S. , Steidley, D. Eric , Clavell, Alfredo L. , Young, Phillip M. , Pereira, Naveen L. , Lemond, Lisa M, Steidley, David E, Clavell, Alfredo, Young, Phillip, Asleh, Rabea , Smith, Byron H.

Mayo Clinic

ESC Heart Failure | February 20, 2024 | Volume: 11 | Issue: 3 | Pages: 1594-1601

10.1002/ehf2.14681 | PMID 38379022 Get It

Abstract Aims Graft dysfunction (GD) after heart transplantation (HTx) can develop without evidence of cell- or antibody-mediated rejection. Cardiac magnetic resonance imaging (CMR) has an evolving role in detecting rejection; however, its role in biopsy-negative GD has not been described. This study examines CMR findings, evaluates outcomes based on CMR results, and seeks to identify the possibility of rejection missed through endomyocardial biopsy by using CMR in HTx recipients with biopsy-negative GD. Methods and results HTx recipients with GD [defined as a decrease in left ventricular ejection fraction (LVEF) by >5% and LVEF < 50%] in the absence of rejection by biopsy or allograft vasculopathy and who underwent CMR were included in the study. The primary outcome was a composite of all-cause mortality, re-transplantation, or persistent LVEF < 50%. Overall, 34 HTx recipients developed biopsy-negative GD and underwent CMR. Left ventricular late gadolinium enhancement (LGE) on CMR was observed in 16 patients with two distinct patterns: diffuse epicardial (n = 13) and patchy (n = 3) patterns. Patients with LGE developed GD later after HTx [4 (1.4–6.8) vs. 0.8 (0.3–1.2) years, P < 0.001], were more often symptomatic (88% vs. 56%, P = 0.06), and had greater haemodynamic derangement (pulmonary capillary wedge pressure: 19 ± 7 vs. 13 ± 3 mmHg, P = 0.002) as compared with those without LGE. No significant difference was observed in the primary composite outcome between patients with LGE and those without LGE (50% vs. 38% of patients with events, P = 0.515). During a median follow-up of 3.8 years, mean LVEF improved similarly in the LGE-negative (37–55%) and LGE-positive groups (32–55%) (P = 0.16). Conclusions Biopsy-negative GD occurs with and without LGE when assessed by CMR, indicative of possible rejection/inflammation occurring only in a subset of patients. Irrespective of LGE, LVEF improvement occurs in most GD patients, suggesting that other neurohormonal or immunomodulatory mechanisms may also contribute to GD development.
The past, present, and future of the brain imaging data structure (BIDS)
Markiewicz, Christopher J. , Bansal, Shashank , Bénar, Christian , Bertazzoli, Giacomo , Bhogawar, Suyash , Blair, Ross , Brooks, Teon L , Calhoun, Vince D. , Castelli, Filippo Maria , D’Ambrosio, Sasha , Hollander, Gilles de , Vega, Alejandro de la , Delorme, Arnaud , Earl, Eric , Feingold, Franklin , Flandin, Guillaume, Galassi, Anthony , Gallitto, Giuseppe , Ganz, Melanie , Gholam, James , Ghosh, Satrajit , Guidali, Giacomo , Handwerker, Daniel A. , Hardcastle, Nell , Innis, Robert B. , Ioanas, Horea-Ioan , Jahn, Andrew , Karakuzu, Agâh , Kincses, Bálint , Lau, Jonathan C. , Li, Xiangrui , Meisler, Steven L. , Mikkelsen, Mark E. , Nichols, Thomas E. , Ort, Eduard , Park, Patrick J., Pawlik, Mateusz , Pestilli, Franco , Pollonini, Luca , Rizzo, Gaia , Robbins, Kay A. , Rockhill, Alexander P. , Rogers, Christine , Rokem, Ariel , Rorden, Chris , Routier, Alexandre , Saborit-Torres, Jose Manuel , Schirner, Michael , Smith, Robert E. , Sprenger, Julia , Szinte, Martin , Thomas, Adam G. , Torabian, Sajjad, Voytek, Bradley , Calhoun, Vince D. , Poldrack, Russell A. , Appelhoff, Stefan , Ashar, Yoni K. , Auer, Tibor , Baillet, Sylvain , Beltrachini, Leandro , Bortoletto, Marta , Boudreau, Mathieu , Clement, Patricia , Cohen, Alexander L. , Cohen-Adad, Julien , Iglesia-Vayá, María de la , Devinsky, Orrin , Draschkow, Dejan , Duff, Eugene Paul , DuPré, Elizabeth , Estéban, Oscar , Gau, Rémi , Ghosh, Satrajit S , Giacomel, Alessio , Gillman, Ashley , Gleeson, Padraig , Gramfort, Alexandre , Guay, Samuel , Halchenko, Yaroslav O. , Herholz, Peer , Hermes, Dora , Honey, Christopher John , Keator, David B. , Kiar, Gregory , Laird, Angela R. , Lazari, Alberto , Legarreta, Jon Haitz , Li, Adam , Love, Bradley C. , Lu, Hanzhang , Marcantoni, Eleonora , Maumet, Camille , Mazzamuto, Giacomo , Mutsaerts, Henk , Nikolaidis, Aki , Nilsonne, Gustav , Niso, Guiomar , Nørgaard, Martin Agge , Okell, Thomas W. , Oostenveld, Robert , Pernet, Cyril R , Petr, Jan , Phillips, Christophe L. M. , Poline, Jean‐Baptiste , Raamana, Pradeep Reddy , Ritter, Petra , Salo, Taylor , Spisák, Tamás , Swann, Nicole C. , Takerkart, Sylvain , Thirion, Bertrand , Varoquaux, Gaël , Welzel, Julius , Wilson, Martin , Yarkoni, Tal , Gorgolewski, Krzysztof J.

Mayo Clinic

Imaging Neuroscience | February 20, 2024 | Volume: 2 | Issue: No issue available | Pages: No page available

10.1162/imag_a_00103 | PMID 39308505 Get It

Abstract The Brain Imaging Data Structure (BIDS) is a community-driven standard for the organization of data and metadata from a growing range of neuroscience modalities. This paper is meant as a history of how the standard has developed and grown over time. We outline the principles behind the project, the mechanisms by which it has been extended, and some of the challenges being addressed as it evolves. We also discuss the lessons learned through the project, with the aim of enabling researchers in other domains to learn from the success of BIDS.
SNOT‐22 subdomain outcomes following treatment for sinonasal malignancy: A prospective, multicenter study
Grimm, David R. , Beswick, Daniel M. , Maoz, Sabrina L. , Chan, Erik, Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Adappa, Nithin D. , Patel, Zara M. , Sim, Myung‐Shin , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Hwang, Peter H. , Wang, Eric W , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Hwang, Peter H , Beswick, Daniel , Grimm, David R , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Abuzeid, Waleed M. , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | February 19, 2024 | Volume: 14 | Issue: 8 | Pages: 1314-1326

10.1002/alr.23338 | PMID 38372441 Get It

AbstractBackgroundPatients with sinonasal malignancy (SNM) present with significant sinonasal quality of life (QOL) impairment. Global sinonasal QOL as measured by the 22‐item Sinonasal Outcomes Test (SNOT‐22) has been shown to improve with treatment. This study aims to characterize SNOT‐22 subdomain outcomes in SNM.MethodsPatients diagnosed with SNM were prospectively enrolled in a multi‐center patient registry. SNOT‐22 scores were collected at the time of diagnosis and through the post‐treatment period for up to 5 years. Multivariable regression analysis was used to identify drivers of variation in SNOT‐22 subdomains.ResultsNote that 234 patients were reviewed, with a mean follow‐up of 22 months (3 months–64 months). Rhinologic, psychological, and sleep subdomains significantly improved versus baseline (all p < 0.05). Subanalysis of 40 patients with follow‐up at all timepoints showed statistically significant improvement in rhinologic, extra‐nasal, psychological, and sleep subdomains, with minimal clinically important difference met between 2 and 5 years in sleep and psychological subdomains. Adjuvant chemoradiation was associated with worse outcomes in rhinologic (adjusted odds ratio (5.22 [1.69–8.66])), extra‐nasal (2.21 [0.22–4.17]) and ear/facial (5.53 [2.10–8.91]) subdomains. Pterygopalatine fossa involvement was associated with worse outcomes in rhinologic (3.22 [0.54–5.93]) and ear/facial (2.97 [0.32–5.65]) subdomains. Positive margins (5.74 [2.17–9.29]) and surgical approach—combined versus endoscopic (3.41 [0.78–6.05])—were associated with worse psychological outcomes. Adjuvant radiation (2.28 [0.18–4.40]) was associated with worse sleep outcomes.ConclusionsSinonasal QOL improvements associated with treatment of SNM are driven by rhinologic, extra‐nasal, psychological, and sleep subdomains.
Ki-67 Proliferation Index Is Associated With Tumor Grade and Survival in Pleural Epithelioid Mesotheliomas
Galeano, Belinda, Smith, Caleb J. , Yi, Eunhee S. , Roden, Anja C. , Jenkins, Sarah M. , Capelle, Jenna, Kittle-Francis, Mary, Aubry, Marie Christine, Mansfield, Aaron S.

Mayo Clinic

American Journal of Surgical Pathology | February 19, 2024 | Volume: 48 | Issue: 5 | Pages: 615-622

10.1097/pas.0000000000002196 | PMID 38369761 Get It

Pleural epithelioid mesothelioma (PEM) is divided into low and high grades based on nuclear atypia, mitoses, and necrosis in the tumor. Assessing mitoses and nuclear atypia tend to be labor-intensive with limited reproducibility. Ki-67 proliferation index was shown to be a prognostic factor in PEM, but its performance has not been directly correlated with tumor grade or mitotic score. This study evaluated the potential of Ki-67 index as a surrogate of tumor grade. We also compared the predictability of mitoses and Ki-67 index for overall survival (OS). Ninety-six PEM samples from 85 patients were identified from the surgical pathology file during 2000-2021 at our institution, and all glass slides were reviewed by 2 pulmonary pathologists to confirm the diagnosis and assign the tumor grade. Digital image analysis (DIA) was done for Ki-67 index. The agreement on tumor grading between 2 reviewers was moderate (kappa value = 0.47). The correlation between mitotic count (average count by 2 reviewers) and Ki-67 index was 0.65. The areas under the curve for predicting tumor grade by mitotic score and Ki-67 index were 0.84 and 0.74 (reviewer 1) and 0.85 and 0.81 (reviewer 2), respectively. High Ki-67 index and mitoses were significantly associated with poor OS (P=0.03 and 0.0005, using 30% and 10/2 mm2 as cutoffs, respectively). In conclusion, Ki-67 index by DIA was associated with tumor grade as well as mitotic count, and its predictability for OS was comparable to that of mitotic score, thus being a potential surrogate for tumor grade.
Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice
Lounev, Vitali, Groppe, Jay C. , Brewer, Niambi , Wentworth, Kelly L. , Smith, Victoria , Xu, Meiqi , Schomburg, Lutz , Bhargava, Pankaj , Mukaddam, Mona Al , Shore, Eileen M. , Pignolo, Robert J. , Hsiao, Edward C. , Kaplan, Frederick S.

Mayo Clinic

Journal of Bone and Mineral Research | February 17, 2024 | Volume: 39 | Issue: 4 | Pages: 382-398

10.1093/jbmr/zjae029 | PMID 38477818 Get It

Abstract Single case studies of extraordinary disease resilience may provide therapeutic insight into conditions for which no definitive treatments exist. An otherwise healthy 35-year-old man (patient-R) with the canonical pathogenic ACVR1R206H variant and the classic congenital great toe malformation of fibrodysplasia ossificans progressiva (FOP) had extreme paucity of post-natal heterotopic ossification (HO) and nearly normal mobility. We hypothesized that patient-R lacked a sufficient post-natal inflammatory trigger for HO. A plasma biomarker survey revealed a reduction in total matrix metalloproteinase-9 (MMP-9) compared to healthy controls and individuals with quiescent FOP. Whole exome sequencing identified compound heterozygous variants in MMP-9 (c.59C &gt; T, p.A20V and c.493G &gt; A, p.D165N). Structural analysis of the D165N variant predicted both decreased MMP-9 secretion and activity that were confirmed by enzyme-linked immunosorbent assay and gelatin zymography. Further, human proinflammatory M1-like macrophages expressing either MMP-9 variant produced significantly less Activin A, an obligate ligand for HO in FOP, compared to wildtype controls. Importantly, MMP-9 inhibition by genetic, biologic, or pharmacologic means in multiple FOP mouse models abrogated trauma-induced HO, sequestered Activin A in the extracellular matrix (ECM), and induced regeneration of injured skeletal muscle. Our data suggest that MMP-9 is a druggable node linking inflammation to HO, orchestrates an existential role in the pathogenesis of FOP, and illustrates that a single patient’s clinical phenotype can reveal critical molecular mechanisms of disease that unveil novel treatment strategies.
Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework
Peipert, John Devin , Basch, Ethan , Cella, David , Smith, Mary Lou , Thanarajasingam, Gita , Peipert, John Devin , Breslin, Monique C. , Basch, Ethan , Calvert, Melanie , Roydhouse, Jessica

Mayo Clinic

Journal of Biopharmaceutical Statistics | February 15, 2024 | Volume: 35 | Issue: 5 | Pages: 793-811

10.1080/10543406.2024.2313060 | PMID 38358291 Get It

Examining crossover and postprotocol therapies in first‐line immunotherapy trials in non–small cell lung cancer
Desai, Aakash , Smith, Caleb J. , Leventakos, Konstantinos , West, Howard , Pritchett, Joshua C. , Desai, Aakash P

Mayo Clinic

Cancer | February 14, 2024 | Volume: 130 | Issue: 16 | Pages: 2807-2811

10.1002/cncr.35250 | PMID 38353476 Get It

AbstractBackgroundImmune checkpoint inhibitor (ICI) therapy has led to significant improvement in outcomes for patients with nononcogene‐driven advanced non–small cell lung cancer (NSCLC). The rate of crossover and receipt of postprotocol ICI in frontline trials for advanced NSCLC has not been systematically evaluated.MethodsClinicalTrials.gov was used to identify phase 3 studies evaluating the use of immunotherapy or combination chemoimmunotherapy against chemotherapy alone in the frontline management of advanced NSCLC. Data on outcomes, rate of crossover and/or subsequent post‐protocol receipt of immunotherapy, and the start dates of these clinical trials were then extracted.ResultsTwenty‐three frontline trials in nononcogene‐driven advanced NSCLC were identified. Six trials with ICI monotherapy/dual ICI therapy and 17 trials evaluating chemotherapy/ICI in first‐line advanced NSCLC were included in the analysis. The crossover rate ranged 0% to 54% in ICI monotherapy/dual ICI trials and 0% to 52% in chemotherapy/ICI trials. Nineteen of 23 trials provided information on subsequent postprotocol therapies. Among the trials not allowing crossover, postprotocol ICI was administered to 17% to 45.8% of patients. Information regarding the eventual receipt of ICI therapy was available for 22 of 23 trials. Of 6631 patients, 2507 (37.8%) randomized to the control arm eventually received ICI therapy.ConclusionThe rate of crossover and postprotocol ICI use was low in frontline trials for first‐line NSCLC incorporating ICI. Given the proven improved overall survival of ICI in a broad population, there is a need to ensure availability of this life‐prolonging therapy in future trials, either by crossover treatment or postprotocol administration.
Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia
Peltenburg, Puck J. , Heuvel, Lieke M. van den , Kallas, Dania , Bell, Cheyanne , Denjoy, Isabelle , Behr, Elijah R. , Kammeraad, Janneke A.E. , Yap, Sing‐Chien , Probst, Vincent , Ackerman, Michael J. , Wilde, Arthur A.M. , van den Heuvel, Lieke M , Kammeraad, Janneke A E , Yap, Sing-Chien , Probst, Vincent , Ackerman, Michael J , Blom, Nico A , Wilde, Arthur A M , Clur, Sally-Ann B , van der Werf, Christian , Behr, Elijah Raphael , Denjoy, Isabelle , Peltenburg, Puck J , Field, Ella , Blom, Nico A. , Clur, Sally‐Ann B. , Werf, Christian van der

Mayo Clinic

Europace | February 13, 2024 | Volume: 26 | Issue: 2 | Pages: No page available

10.1093/europace/euae044 | PMID 38349347 Get It

Abstract Aims In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited arrhythmia syndrome, arrhythmic events can be prevented by medication and lifestyle recommendations. In patients who experience breakthrough arrhythmic events, non-adherence plays an essential role. We aimed to investigate the incidence and potential reasons for non-adherence to medication and lifestyle recommendations in a large, international cohort of patients with CPVT. Methods and results An online multilingual survey was shared with CPVT patients worldwide by their cardiologists, through peer-recruitment, and on social media from November 2022 until July 2023. Self-reported non-adherence was measured using the validated Medication Adherence Rating Scale (MARS) and a newly developed questionnaire about lifestyle. Additionally, validated questionnaires were used to assess potential reasons for medication non-adherence. Two-hundred-and-eighteen patients completed the survey, of whom 200 (92%) were prescribed medication [122 (61%) female; median age 33.5 years (interquartile range: 22–50)]. One-hundred-and-three (52%) were prescribed beta-blocker and flecainide, 85 (43%) beta-blocker, and 11 (6%) flecainide. Thirty-four (17%) patients experienced a syncope, aborted cardiac arrest or appropriate implantable cardioverter defibrillator shock after diagnosis. Nineteen (13.4%) patients were exercising more than recommended. Thirty (15%) patients were non-adherent to medication. Female sex [odds ratio (OR) 3.7, 95% confidence interval (CI) 1.3–12.0, P = 0.019], flecainide monotherapy compared to combination therapy (OR 6.8, 95% CI 1.6–31.0, P = 0.010), and a higher agreement with statements regarding concerns about CPVT medication (OR 1.2, 95% CI 1.1–1.3, P &lt; 0.001) were independently associated with non-adherence. Conclusion The significant rate of non-adherence associated with concerns regarding CPVT-related medication, emphasizes the potential for improving therapy adherence by targeted patient education.
Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers
Minervini, Marta I., Demetris, Anthony J. , Neil, Desley , Smith, Maxwell L.

Mayo Clinic

Hepatology | February 13, 2024 | Volume: 80 | Issue: 1 | Pages: E6-E7

10.1097/hep.0000000000000788 | PMID 38349643 Get It